As BCL2 and cellular apoptosis played a central role in HCC cell response to sorafenib (37), we next explored potential role of KDM1A–FKBP8–BCL2 axis in sorafenib response and resistance, which was clinically relevant. The gene discussed is BCL2; the disease is hepatocellular carcinoma.